Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: A meta-analysis

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 3, 2014, Pages 852-860

  Barake, Maya ^a,b   Klibanski, Anne ^a   Tritos, Nicholas A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Bellevue Medical Center   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GROWTH HORMONE;

AGE; ARTICLE; BONE DENSITY; CLINICAL STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFECT; FEMUR NECK FRACTURE; FRACTURE; GENDER; GROWTH HORMONE DEFICIENCY; HUMAN; LUMBAR SPINE; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SPINE FRACTURE; TREATMENT DURATION;

ADULT; AGED; BONE DENSITY; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84895825315     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3921     Document Type: Article

References (49)

1. Harris WH, Heaney RP. Effect of growth hormone on skeletal mass in adult dogs. Nature. 1969;223:403-404.
2. Baroncelli GI, Bertelloni S, Sodini F, Saggese G. Acquisition of bone mass in normal individuals and in patients with growth hormone deficiency. J Pediatr Endocrinol Metab. 2003;16(suppl 2):327-335. (Pubitemid 37264914)
3. Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab. 1998;83:382-395. (Pubitemid 28496511)
4. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab. 1994;78:669-674. (Pubitemid 24083309)
5. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol. 1997;137: 240-245. (Pubitemid 27405107)
6. Vestergaard P, Jorgensen JO, Hagen C, et al. Fracture risk is increased in patients with GH deficiency or untreated prolactinomas- a case-control study. Clin Endocrinol (Oxf). 2002;56:159-167. (Pubitemid 34234798)
7. Wuster C, Abs R, Bengtsson BA, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res. 2001;16:398-405. (Pubitemid 32106717)
8. Gharib H, Cook DM, Saenger PH, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children-2003 update. Endocr Pract. 2003;9:64-76.
9. Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007;157:695-700.
10. Elbornsson M, Gotherstrom G, Bosaeus I, Bengtsson BA, Johannsson G, Svensson J. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol. 2012;166:787-795.
11. Hazem A, ElaminMB,Bancos I, et al. Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur J Endocrinol. 2012;166:13-20.
12. Davidson P, Milne R, Chase D, Cooper C. Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2004;60:92-98. (Pubitemid 38183504)
13. Colson A, BrookeAM,Walker D, et al. Growth hormone deficiency and replacement in patients with treated Cushing's disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density. Horm Res. 2006;66:257-267. (Pubitemid 44801336)
14. Johannsson G, Sunnerhagen KS, Svensson J. Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease. Clin Endocrinol (Oxf). 2004;60:550-559. (Pubitemid 38678637)
15. Longobardi S, Di Rella F, Pivonello R, et al. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients. J Endocrinol Invest. 1999;22:333-339. (Pubitemid 29259554)
16. Rossini A, Lanzi R, Losa M, et al. Predictors of bone responsiveness to growth hormone (GH) replacement in adult GH-deficient patients. Calcif Tissue Int. 2011;88:304-313.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188. (Pubitemid 17189972)
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558. (Pubitemid 34746062)
19. Beckers V, Milet J, Legros JJ. Prolonged treatment with recombined growth hormone improves bone measures: study of body composition in 21 deficient adults on treatment. Ann Endocrinol (Paris). 2001;62:507-515. (Pubitemid 34056631)
20. Biller BM, Sesmilo G, Baum HB, Hayden D, Schoenfeld D, Klibanski A. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab. 2000;85:970-976. (Pubitemid 32269335)
21. Cuneo RC, Judd S, Wallace JD, et al. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults. J Clin Endocrinol Metab. 1998;83:107-116. (Pubitemid 28498319)
22. Finkenstedt G, Gasser RW, Hofle G, Watfah C, Fridrich L. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up. Eur J Endocrinol. 1997;136:282-289. (Pubitemid 27130052)
23. Gomez JM, Gomez N, Fiter J, Soler J. Effects of long-term treatment withGHin the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement. Horm Metab Res. 2000;32:66-70. (Pubitemid 30143611)
24. Janssen YJ, Hamdy NA, Frolich M, Roelfsema F. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency. J Clin Endocrinol Metab. 1998;83:2143-2148. (Pubitemid 28496351)
25. Johansson AG, Engstrom BE, Ljunghall S, Karlsson FA, Burman P. Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. J Clin Endocrinol Metab. 1999;84:2002-2007. (Pubitemid 30647025)
26. Kotzmann H, Riedl M, Bernecker P, et al. Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency. Calcif Tissue Int. 1998;62:40-46. (Pubitemid 28018674)
27. Luisetto G, ZaccariaM,Cestaro S, Camozzi V, Angelini F, Moise M. Effect of growth hormone replacement therapy on bone mass, bone metabolism, and body composition in adult patients with growth homone deficiency. Current Therapeutic Res. 1999;60:237-249. (Pubitemid 29186445)
28. Rodriguez-Arnao J, James I, Jabbar A, et al. Serum collagen crosslinks as markers of bone turn-over during GH replacement therapy in growth hormone deficient adults. Clin Endocrinol (Oxf). 1998; 48:455-462. (Pubitemid 28258818)
29. Sartorio A, Ortolani S, Conti A, Cherubini R, Galbiati E, Faglia G. Effects of recombinant growth hormone (GH) treatment on bone mineral density and body composition in adults with childhood onset growth hormone deficiency. J Endocrinol Invest. 1996;19: 524-529. (Pubitemid 26372265)
30. Thoren M, Soop M, Degerblad M, Saaf M. Preliminary study of the effects of growth hormone substitution therapy on bone mineral density and serum osteocalcin levels in adults with growth hormone deficiency. Acta Endocrinol (Copenh). 1993;128(suppl 2:41-43.
31. Arwert LI, Roos JC, Lips P, Twisk JW, Manoliu RA, Drent ML. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin Endocrinol (Oxf). 2005;63:310-316. (Pubitemid 41233449)
32. Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Miner Res. 2002;17:1081- 1094.
33. Boguszewski CL, Meister LH, Zaninelli DC, Radominski RB. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol. 2005;152:67-75. (Pubitemid 40192469)
34. Bravenboer N, Holzmann PJ, ter Maaten JC, Stuurman LM, Roos JC, Lips P. Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J Bone Miner Res. 2005;20:1778-1784. (Pubitemid 41361878)
35. Clanget C, Seck T, Hinke V, Wuster C, Ziegler R, Pfeilschifter J. Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. Clin Endocrinol (Oxf). 2001; 55:93-99. (Pubitemid 34204304)
36. Drake WM, Rodriguez-Arnao J, Weaver JU, et al. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study. Clin Endocrinol (Oxf). 2001;54:525-532. (Pubitemid 34207705)
37. Gotherstrom G, Svensson J, Koranyi J, et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab. 2001;86:4657-4665. (Pubitemid 33026070)
38. Rota F, Savanelli MC, Tauchmanova L, et al. Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender. J Endocrinol Invest. 2008;31:94-102.
39. Sartorio A, Ortolani S, Galbiati E, et al. Effects of 12-month GH treatment on bone metabolism and bone mineral density in adults with adult-onset GH deficiency. J Endocrinol Invest. 2001;24:224-230. (Pubitemid 32435501)
40. Snyder PJ, Biller BM, Zagar A, et al. Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency. J Bone Miner Res. 2007;22:762-770. (Pubitemid 351339106)
41. Tanriverdi F, Unluhizarci K, Kula M, Guven M, Bayram F, Kelestimur F. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome. Growth Horm IGF Res. 2005;15:231-237. (Pubitemid 40754126)
42. Zaninelli DC, Meister LH, Radominski RB, Borba VZ, Souza AM, Boguszewski CL. Efficacy, safety and compliance of long-term growth hormone (GH) replacement therapy in adults with GH deficiency. Arq Bras Endocrinol Metab. 2008;52:879-888.
43. Cabo D, Lecube A, Barrios M, Mesa J. Long term treatment with growth hormone deficiency in adults. Med Clin (Barc). 2011;136: 659-664.
44. Jorgensen AP, Fougner KJ, Ueland T, et al. Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. Growth Horm IGF Res. 2011;21:69-75.
45. Tritos NA, Biller BM. Growth hormone and bone. Curr Opin Endocrinol Diabetes Obes. 2009;16:415-422.
46. Ortolani S. Bone densitometry: assessing the effects of growth hormone treatment in adults. Horm Res. 2000;54(suppl 1):19 -23.
47. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1587-1609.
48. Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely A, Hartman ML. Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab. 2004;89:3224-3233. (Pubitemid 38960691)
49. Klefter O, Feldt-Rasmussen U. Is increase in bone mineral content caused by increase in skeletal muscle mass/strength in adult patients with growth hormone (GH) treated GH deficiency? A systematic literature analysis. Eur J Endocrinol. 2009;161(2):213-221.